| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4bb6c22d9b6c8c5ab3926f98ba512aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b68f9bf2f758c477bd74f81c256a56b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-54 |
| filingDate |
1999-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea655100c9bdffdf3548e00bd5db9ab9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6c325bb37573511d88f7a8bf7852768 |
| publicationDate |
2000-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0029386-A1 |
| titleOfInvention |
Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists |
| abstract |
Novel pyrimidinedione compounds and pharmaceutically acceptable salts thereof are disclosed. The synthesis of these compounds and their use as alpha 1a adrenergic receptor antagonists is also described. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia can be achieved. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6872728-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10568871-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7179815-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4673847-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007521307-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6608197-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11666557-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2992883-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0155119-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9676754-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7462625-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003520856-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9776976-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9505728-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100814269-B1 |
| priorityDate |
1998-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |